Four new administrators named

BIOQuébec’s Board of Directors Consolidates Its Support for the Strategic Development of Québec’s Biotechnology and Life Sciences Network

BROMONT (Québec) September 23, 2016 – Martin Godbout, O.C., PhD., President of BIOQuébec’s board of directors, has announced the nomination of Frederic Fasano, President and CEO of Servier Canada Inc., of François Laflamme, Senior Executive in charge of governmental relations at Eli Lilly Inc., of Martin Leblanc, President of Caprion Biosciences Inc., and of Frédéric Leduc, President of Immune Biosolutions Inc., as members of its board of directors, effective immediately. 

“I am pleased to welcome Mr. Fasano, Mr. Laflamme, Mr. Leblanc, and Mr. Leduc to BIOQuébec’s board of directors”, said Mr. Godbout. “The experience and the expertise they have acquired while holding leadership positions at organizations of various sizes, as well as their wide range of knowledge of innovation research and financing, enrich the composition of our board of directors.” 

Frederic Fasano has more than 22 years of experience in the pharmaceutical industry, including 20 years with the Servier research group, a French pharmaceutical research company. He holds a State degree from the Université de Paris Xl Chatenay-Malabry and a MBA from ESSEC. He has acquired extensive worldwide experience while at the helm of several of the group’s affiliates. 

François Laflamme has spent more than 20 years at Eli Lilly, a pharmaceutical company currently celebrating its 140th anniversary. Over the years, he has overseen drug production operations, finance, sales, hospital partnership strategies, and product reimbursements before being assigned to government relations. His current duties focus on Lilly’s innovation strategy in Canada. He holds a MBA from Western University’s Ivey Business School. He is also a member of the Schmeelk Fellowship’s board of directors and is Chairman of its selection committee.

Co-founder of Caprion, Martin Leblanc has spent more than 15 years as head of this specialized services company which concentrates on proteomics, immune surveillance, and personalized medicine laboratory research. A member of several boards of directors, of the Canadian Institutes of Health Research (CIHR) board of governors, and of AmorChem Fund’s Investment Committee, Mr. Leblanc holds a Bachelor of Economic Science degree from the Université de Moncton as well as a Master’s Degree in Economic and Political Science from Oxford University, where he was a Rhodes Scholar. 

Frédéric Leduc is President and CEO of Immune BioSolutions, a Sherbrooke-based biotech that creates the best chicken antibodies to target traditionally difficult therapies in order to explore and solve global 

health issues. He holds a Doctorate in Biochemistry from the Université de Sherbrooke and has received many awards since he founded his company, including the Grand Prize at the Youth Entrepreneurship Challenge in 2013. 

BIOQuébec’s board of directors consists of members from all levels of the life sciences innovation chain, from discovery to marketing; as such, they are able to provide strong and pertinent support for BIOQuébec’s strategic development. 

BIOQuébec: A Dynamic Network
BIOQuébec is committed to supporting the growth of Québec’s biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone’s health and quality of life. For more information, go to 


Anie Perrault, LL.L., ASC
Executive Manager | T. 514-360-4565 | C. 450 522-0615 

1460, boulevard de l’Innovation, suite 205
Bromont (Québec) J2L 0J8